Format

Send to

Choose Destination
Arthritis Res Ther. 2015 May 20;17:125. doi: 10.1186/s13075-015-0638-x.

Associations of antibodies against citrullinated peptides with human leukocyte antigen-shared epitope and smoking prior to the development of rheumatoid arthritis.

Author information

1
Institution of Public Health and Clinical Medicine/Rheumatolgy, Umeå University, SE-90185, Umeå, Sweden. heidi.kokkonen@umu.se.
2
Institution of Public Health and Clinical Medicine/Rheumatolgy, Umeå University, SE-90185, Umeå, Sweden. mikael.brink@medicin.umu.se.
3
Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden. monika.hansson@ki.se.
4
Institution of Public Health and Clinical Medicine/Rheumatolgy, Umeå University, SE-90185, Umeå, Sweden. ewa.lassen@vll.se.
5
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. linda.mathsson-alm@thermofisher.com.
6
Thermo Fisher Scientific, Uppsala, Sweden. linda.mathsson-alm@thermofisher.com.
7
Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden. rikard.holmdahl@ki.se.
8
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. johan.ronnelid@igp.uu.se.
9
Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden. lars.klareskog@ki.se.
10
Institution of Public Health and Clinical Medicine/Rheumatolgy, Umeå University, SE-90185, Umeå, Sweden. solbritt.rantapaa.dahlqvist@umu.se.

Abstract

INTRODUCTION:

It has previously been shown that an increased number of antibodies against citrullinated peptides/proteins (ACPA) predate the onset of rheumatoid arthritis (RA). Over time antibody positivity expands, involving more specific responses when approaching the onset of symptoms. We investigated the impact of human leukocyte antigen-shared epitope (HLA-SE) alleles and smoking on the development of ACPA, as well as in combination with ACPA during the state of quiescent autoimmunity (before the onset of symptoms), on the development of RA.

METHODS:

Blood samples donated to the Medical Biobank of Northern Sweden from individuals prior to the onset of symptoms of RA (n=370) and after onset (n=203) and from population-based controls (n=585) were used. Antibodies against 10 citrullinated peptides, fibrinogen (Fibα561-583, α580-600, ß62-81a, ß62-81b, ß36-52), vimentin (Vim2-17, 60-75), filaggrin (CCP-1/Fil307-324), α-enolase (CEP-1/Eno5-21), collagen type II (citC1359-369), and anti-cyclic citrullinated peptide (CCP)2 antibodies were analysed.

RESULTS:

HLA-SE-positive individuals were more frequently positive for ACPA compared with HLA-SE-negative individuals prior to the onset of symptoms of RA, particularly for antibodies against CEP-1 and Fibß62-81a (72). Smoking was associated with antibodies against Vim2-17 and citC1359-369. HLA-SE and smoking showed increasing association to the presence of the antibodies closer to disease onset. The highest odds ratio (OR) for development of RA was for the combination of HLA-SE alleles and ACPA positivity, especially for antibodies against Fibß62-81b, CCP-1/Fil307-324, and Fibβ36-52. A gene-environment additive interaction between smoking and HLA-SE alleles for the risk of disease development was found, with the highest OR for individuals positive for antibodies against Fibβ36-52, CEP-1, and Fibα580-600.

CONCLUSIONS:

The relationships between antibodies against the different ACPA specificities, HLA-SE, and smoking showed a variable pattern in individuals prior to the onset of RA. The combination of smoking and HLA-SE alleles was significantly associated with the development of some of the antibody specificities closer to onset of symptoms, and these associations remained significant at diagnosis. An additive gene-environment interaction was found for several of the antibodies for the development of RA.

PMID:
25990747
PMCID:
PMC4438519
DOI:
10.1186/s13075-015-0638-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center